Purchase this article with an account.
kaline sandrelli amorim ferreira, Rodrigo Pessoa Cavalcanti Lira, Nelise De paiva Lucena, Bruna Marília Alves dos Santos; OCULAR DELIVERY OF MOXIFLOXACIN-LOADED LIPOSOMES. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4451.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to study the release profile of moxifloxacin encapsulated in liposomes in the aqueous humor as a controlled release system for intracameral application
Liposomes containing moxifloxacin (MFLX-Lipo) were obtained using the lipid film hydration method and were characterized by particle size and encapsulation efficiency. Fifteen female rabbits were used for the in vivo profile release study. MFLX-Lipo was injected into the anterior chamber of each animal’s right eye. The rabbits were divided into 5 groups, and a sample of aqueous humor (AH) was collected 2, 4, 8, 24, and 48 hours after MFLX-Lipo administration. Moxifloxacin (MFLX) concentrations in the AH were analyzed using high performance liquid chromatography.
MFLX-Lipo exhibited an average size of 60.5 ± 0.72 nm and a particle size distribution of 0.307. The encapsulation efficiency of MFLX in liposomes was 92.24 ± 0.24%. In the in vivo release study of MFLX-Lipo, the maximum concentration of MFLX was achieved within the first 2 hours after administration (5.27 ± 1.09 mg/mL) and was followed by a decrease in intracameral concentration (0.35 ± 0.05 mg/mL) until the 48-hour mark.
The liposomal formulation obtained exhibits properties that make it suitable for administration via a topical ophthalmic route and offers stability and high encapsulation efficiency. In the in vivo study, MFLX-Lipo exhibited a satisfactory aqueous humor release profile, which suggests that it is an option for the prophylaxis of frequent endophthalmitis pathogens.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only